PolyNovo Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Swami Raote

Algemeen directeur

AU$1.5m

Totale compensatie

Percentage CEO-salaris	46.4%
Dienstverband CEO	2.3yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.2yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Swami Raote's beloning veranderd ten opzichte van PolyNovo's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$2m	AU$707k	AU$5m
Mar 31 2024	n/a	n/a	AU$3m
Dec 31 2023	n/a	n/a	AU$2m
Sep 30 2023	n/a	n/a	-AU$2m
Jun 30 2023	AU$2m	AU$617k	-AU$5m

Compensatie versus markt: De totale vergoeding ($USD 990.35K ) Swami } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.46M ).

Compensatie versus inkomsten: De vergoeding van Swami is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Swami Raote

2.3yrs

Tenure

AU$1,523,944

Compensatie

Mr. Swami Raote, B. Pharmacy, M.B.A, serves as Director at PolyNovo Limited since September 2022. He serves Entrepreneurs in Residence at DigitalDx Ventures. He serves as Chief Executive Officer at PolyNov...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Swami Raote	CEO & Director	2.3yrs	AU$1.52m	geen gegevens
Jan-Marcel Gielen	Chief Financial Officer	5.9yrs	AU$371.95k	0.093% € 797.0k
David McQuillan	Chief Technical & Scientific Officer	2.2yrs	AU$538.84k	0.097% € 825.6k
Philip Scorgie	Chief Information Officer	1.5yrs	AU$329.02k	geen gegevens
Lior Harel	General Counsel & Company Secretary	less than a year	geen gegevens	geen gegevens
Ingrid Anderson	Chief People Officer	less than a year	geen gegevens	geen gegevens
Edward Graubart	President of North America	5.2yrs	geen gegevens	geen gegevens
Ahmed Hassan	Chief Manufacturing & Supply Chain Officer	less than a year	geen gegevens	geen gegevens
Joseph Amaral	Chief Medical Officer	less than a year	geen gegevens	geen gegevens
David Morris	President of Asia Pacific	less than a year	geen gegevens	geen gegevens

1.2yrs

Gemiddelde duur

Ervaren management: Het managementteam van MFJ wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Swami Raote	CEO & Director	2.2yrs	AU$1.52m	geen gegevens
Robyn Elliott	Independent Non-Executive Director	5.1yrs	AU$95.00k	0.011% € 92.4k
David Williams	Independent Non-Executive Chairman	10.8yrs	AU$139.43k	3.1% € 26.5m
Andrew Lumsden	Independent Non-Executive Director	3.4yrs	AU$95.00k	0.014% € 123.6k
Leon Hoare	Independent Non-Executive Director	8.8yrs	AU$95.02k	0.16% € 1.4m
Christine Emmanuel-Donnelly	Independent Non-Executive Director	4.5yrs	AU$95.00k	0.039% € 334.6k

4.8yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van MFJ wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

PolyNovo Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Independent Non-Executive Director recently sold €161k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold €1.1m worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

Insufficient new directors

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Recent updates

Independent Non-Executive Director recently sold €161k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold €1.1m worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

Full year 2024 earnings released: EPS: AU$0.008 (vs AU$0.007 loss in FY 2023)

Now 23% undervalued

PolyNovo Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Insufficient new directors

Now 24% undervalued after recent price drop

Now 24% undervalued

Now 22% undervalued

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

Now 20% undervalued

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.002 loss in FY 2022)

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Independent Non-Executive Chairman recently sold €6.0m worth of stock

Now 21% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2024

Independent Non-Executive Chairman recently bought €131k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.007 loss in FY 2021)

PolyNovo Limited Announces First Patient Enrolled in Clinical Trial of NovoSorb SynPath Treatment for Diabetic Foot Ulcers

PolyNovo Limited Announces CEO Changes

PolyNovo Limited Announces CEO Changes

Independent Non-Executive Chairman recently bought €294k worth of stock

First half 2022 earnings: EPS in line with expectations, revenues disappoint

PolyNovo Limited Announces First Patient Enrolled in Pivotal Trial of the BARDA Funded Burn Study

Forecast to breakeven in 2023

Full year 2021 earnings released

PolyNovo Limited Provides an Update on its Hernia Device

Non-Executive Independent Director recently sold €369k worth of stock

Independent Non-Executive Chairman recently bought €467k worth of stock

PolyNovo Announces It has Received Final Independent Review Board

First half 2021 earnings released: AU$0.005 loss per share (vs AU$0.004 loss in 1H 2020)

Revenue beats expectations

New 90-day low: €1.53

New 90-day high: €2.16

PolyNovo Limited Announces the Breast Device Development Program with Establishment Labs

Non-Executive Independent Director recently sold €728k worth of stock

PolyNovo Limited Announces US FDA Approves Pivotal Trial IDE

New 90-day high: €1.69

New 90-day high: €1.50

PolyNovo Appoints Innova Medical Oy to Sell Novosorb® BTM in Finland

Independent Non-Executive Chairman recently bought €626k worth of stock

New 90-day low - €1.22

Earnings released

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur